PW Medtech Group Limited provided earnings guidance for the year ended December 31, 2023. The Group is expected to record (i) a net profit in the range of RMB 192 million to RMB 215 million for the year ended December 31, 2023, representing an increase of 49% to 67% as compared to that of approximately RMB129 million for the year ended December 31, 2022, and (ii) a profit attributable to owners of the Company in the range of RMB 142 million to RMB 165 million for the year ended December 31, 2023, representing an increase of 33% to 55% as compared to that of approximately RMB 106 million for the year ended December 31, 2022. Such increase is primarily due to a significant increase in the profit contributed by the Group's blood purification business and the infusion set business.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.03 HKD | 0.00% | +9.57% | +25.61% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.61% | 206M | |
+9.48% | 27.43B | |
-28.65% | 3.18B | |
-16.08% | 2.53B | |
+19.05% | 2.49B | |
+11.11% | 2.16B | |
-4.24% | 2.03B | |
+5.56% | 1.61B | |
+1.69% | 1.31B | |
+29.73% | 1.29B |
- Stock Market
- Equities
- 1358 Stock
- News PW Medtech Group Limited
- PW Medtech Group Limited Provides Earnings Guidance for the Year Ended December 31, 2023